Switch theme
Sign up to access all valuation multiples
Acurx Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention and Food and Drug Administration. The company's approach is to develop antibiotic candidates with a Gram-positive selective spectrum. The Company’s segment consists of the development of clinical and preclinical product candidates for the development of the Company’s proprietary new therapies.
2017
4
Last FY Revenue n/a
Last FY EBITDA -$14.1M
$4.5M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
In the most recent fiscal year, Acurx Pharmaceuticals achieved revenue of n/a and an EBITDA of -$14.1M.
Acurx Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Acurx Pharmaceuticals valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA | n/a | XXX | -$14.1M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBIT | -$13.4M | XXX | -$14.1M | XXX | XXX | XXX |
| EBIT Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| Net Profit | -$13.4M | XXX | -$14.1M | XXX | XXX | XXX |
| Net Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Acurx Pharmaceuticals's stock price is $0.
Acurx Pharmaceuticals has current market cap of $9.1M, and EV of $4.5M.
See Acurx Pharmaceuticals trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $4.5M | $9.1M | XXX | XXX | XXX | XXX | $-0.73 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Acurx Pharmaceuticals has market cap of $9.1M and EV of $4.5M.
Acurx Pharmaceuticals's trades at n/a EV/Revenue multiple, and -0.3x EV/EBITDA.
Equity research analysts estimate Acurx Pharmaceuticals's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Acurx Pharmaceuticals has a P/E ratio of -0.7x.
See valuation multiples for Acurx Pharmaceuticals and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $9.1M | XXX | $9.1M | XXX | XXX | XXX |
| EV (current) | $4.5M | XXX | $4.5M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | n/a | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | -0.3x | XXX | XXX | XXX |
| EV/EBIT | -0.3x | XXX | -0.3x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | -0.7x | XXX | -0.6x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -0.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialAcurx Pharmaceuticals's revenue per employee in the last FY averaged n/a, while opex per employee averaged $3.5M for the same period.
Acurx Pharmaceuticals's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Acurx Pharmaceuticals's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Acurx Pharmaceuticals and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $3.5M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Acurx Pharmaceuticals acquired XXX companies to date.
Last acquisition by Acurx Pharmaceuticals was XXXXXXXX, XXXXX XXXXX XXXXXX . Acurx Pharmaceuticals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Acurx Pharmaceuticals founded? | Acurx Pharmaceuticals was founded in 2017. |
| Where is Acurx Pharmaceuticals headquartered? | Acurx Pharmaceuticals is headquartered in United States of America. |
| How many employees does Acurx Pharmaceuticals have? | As of today, Acurx Pharmaceuticals has 4 employees. |
| Who is the CEO of Acurx Pharmaceuticals? | Acurx Pharmaceuticals's CEO is Mr. David P. Luci. |
| Is Acurx Pharmaceuticals publicy listed? | Yes, Acurx Pharmaceuticals is a public company listed on NAS. |
| What is the stock symbol of Acurx Pharmaceuticals? | Acurx Pharmaceuticals trades under ACXP ticker. |
| When did Acurx Pharmaceuticals go public? | Acurx Pharmaceuticals went public in 2021. |
| Who are competitors of Acurx Pharmaceuticals? | Similar companies to Acurx Pharmaceuticals include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Acurx Pharmaceuticals? | Acurx Pharmaceuticals's current market cap is $9.1M |
| Is Acurx Pharmaceuticals profitable? | Yes, Acurx Pharmaceuticals is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
